AbCellera Biologics (ABCL) EPS (Basic) (2020 - 2023)
Historic EPS (Basic) for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$0.17.
- AbCellera Biologics' EPS (Basic) fell 7000.0% to -$0.17 in Q4 2023 from the same period last year, while for Dec 2023 it was -$0.52, marking a year-over-year decrease of 19285.71%. This contributed to the annual value of -$0.55 for FY2024, which is 784.31% down from last year.
- AbCellera Biologics' EPS (Basic) amounted to -$0.17 in Q4 2023, which was down 7000.0% from -$0.1 recorded in Q3 2023.
- AbCellera Biologics' EPS (Basic)'s 5-year high stood at $0.59 during Q1 2022, with a 5-year trough of -$0.17 in Q4 2023.
- Its 4-year average for EPS (Basic) is $0.07, with a median of -$0.02 in 2020.
- Per our database at Business Quant, AbCellera Biologics' EPS (Basic) skyrocketed by 440000.0% in 2021 and then plummeted by 42833.87% in 2023.
- AbCellera Biologics' EPS (Basic) (Quarter) stood at $0.52 in 2020, then crashed by 57.69% to $0.22 in 2021, then plummeted by 145.45% to -$0.1 in 2022, then plummeted by 70.0% to -$0.17 in 2023.
- Its EPS (Basic) stands at -$0.17 for Q4 2023, versus -$0.1 for Q3 2023 and -$0.11 for Q2 2023.